Medivir Fostrox + Lenvima Trial Shows Improvement In Clinical Benefit In Hepatocellular Carcinoma
Kort samengevat
Medivir AB (MVRBF.PK), a Swedish pharmaceutical company focused on cancer treatments, Tuesday announced that its ongoing phase 1b/2a study with Fostrox + Lenvima demonstrated further improvement in durable clinical benefit in advanced hepatocellular carcinoma or HCC.
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij RTTNews.
Lees het volledige bericht ↗